Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide.
At Plus Therapeutics, we remain committed to advancing the science and support needed to meet the urgent, unmet needs in GBM treatment. Our lead investigational therapy, REYOBIQ™ (rhenium Re186 obisbemeda), is currently being evaluated in the RESPECT-GBM Phase 2 clinical trial, which focuses on treating patients with recurrent glioblastoma using targeted radiotherapeutics delivered directly to the tumor site.
In recognition of today’s awareness efforts, we are proud to spotlight a recent interview with Dr. Andrew Brenner, M.D., Ph.D., one of our Principal Investigators from UT Health San Antonio, who spoke with Cancer Network about the role of REYOBIQ in patient care. In the video, Dr. Brenner explains how REYOBIQ can be visualized using SPECT imaging, allowing clinicians to track its biodistribution and potentially improve treatment precision for GBM patients.
Watch the full interview with Dr. Brenner here:
Cancer Network Video Interview
Join the RESPECT-GBM Trial
The RESPECT-GBM trial is actively recruiting eligible patients. This study is helping to inform future treatment strategies for recurrent glioblastoma and may offer patients access to an innovative therapy under clinical investigation.
Learn more and explore eligibility at:
respect-trials.com/gbm
Or contact our team directly at respect@plustherapeutics.com
Recent Comments